Drug Information

Drug General Information
Drug ID
D04KNL
Former ID
DIB016834
Drug Name
PG-545
Synonyms
PG-457; PG-500; PG-501; PG-502; PG-503; PG-504; PG-505; PG-506; PG-507; PG-508; PG-509; PG-510; PG-511; PG-512; PG-513; PG-514;PG-536; PG-546; PG-547; PG-554; PG-562; PG-500 series (heparan sulfate mimetics), Progen
Indication Ocular disease [ICD10:H00-H59] Phase 1 [531352]
Company
Progen Pharmaceuticals Ltd
Structure
Download
2D MOL
Canonical SMILES
[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[<br />Na+].[Na+].[Na+].[Na+].O=S(=O)(O[C@H]1C(O[C@H]2[C@H]([C<br />@@H]([C@H](OC2OCCCCCCCC)COS(=O)(=O)[O-])OS(=O)(=O)[O-])<br />OS(=O)(=O)[O-])O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2[C<br />@@H]([C@@H](O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)COS(=O)<br />(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])[<br />C@@H]([C@@H](COS(=O)(=O)[O-])O2)OS(=O)(=O)[O-])OS(=O)(=<br />O)[O-])[C@@H]1OS(=O)(=O)[O-])[O-]
Target and Pathway
Target(s) Heparanase Target Info Modulator [531352]
KEGG Pathway Glycosaminoglycan degradation
Metabolic pathways
Proteoglycans in cancer
Pathway Interaction Database Syndecan-1-mediated signaling events
Reactome HS-GAG degradation
WikiPathways Glycosaminoglycan metabolism
References
Ref 531352PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer. 2011 Feb 15;104(4):635-42.
Ref 531352PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer. 2011 Feb 15;104(4):635-42.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.